Boothbay Fund Management, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Boothbay Fund Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.12 - $8.19 $176,020 - $281,564	-34,379 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.68 - $9.1 $42,618 - $58,058	6,380 Added 22.79%	34,379 $230,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $9.23 $85,269 - $100,643	10,904 Added 63.78%	27,999 $239,000
Q1 2021 May 17, 2021	BUY	$8.44 - $12.66 $144,281 - $216,422	17,095 New	17,095 $151,000
Q4 2020 Feb 12, 2021	SELL	$7.98 - $12.29 $302,027 - $465,151	-37,848 Closed	0 $0

Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $203,998 - $318,299	25,628 Added 209.72%	37,848 $308,000
Q2 2020 Aug 14, 2020	SELL	$5.4 - $13.37 $972 - $2,406	-180 Reduced 1.45%	12,220 $117,000
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $60,884 - $182,280	12,400 New	12,400 $84,000
Q1 2019 May 15, 2019	SELL	$10.31 - $14.38 $472,847 - $659,509	-45,863 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$8.63 - $12.4 $395,797 - $568,701	45,863 New	45,863 $466,000
Q3 2018 Nov 14, 2018	SELL	$9.6 - $12.9 $191,462 - $257,277	-19,944 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$8.3 - $16.8 $165,535 - $335,059	19,944 New	19,944 $243,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $492M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.